We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App




Saliva Dipstick Predicts Heart Failure Risk

By HospiMedica International staff writers
Posted on 04 Sep 2019
Print article
Image: The two parts of the ESN device (Photo courtesy of Adam R. Thomas/RMIT).
Image: The two parts of the ESN device (Photo courtesy of Adam R. Thomas/RMIT).
A handheld diagnostic stick with embedded nano-sensors detects biomarkers that can accurately predict the risk of heart disease from saliva.

The ESN Cleer (Melbourne, Australia) device, developed in collaboration with the Innovative Manufacturing Cooperative Research Centre (IMCRC; Melbourne, Australia) and RMIT University (RMIT; Melbourne, Australia), is based on sensing technology originally developed at the RMIT Micro Nano Research Facility. A combination of novel nanomaterials, micro-electrodes, and innovative surface treatments were used to create the sensors, which can be tailored to measure biomarkers of interest, from medically recognized inflammatory markers to proprietary panels that improve prediction accuracy.

To use the device, the user unsnaps the top, which acts as a consumable saliva specimen collector and holds the biosensor array. The end is licked and replaced into the reusable electronics stick, which controls the analysis. After biomarker identification, the result is sent to a dedicated app installed onto a smartphone or tablet device. The app offers multifaceted features, including disease risk level detection report, immediate doctors communications support, an age/demographic statistical comparison, health tracking capabilities, health and wellbeing related informatics, a community interactive interface, and user feedback capabilities.

“Of the 400 million people who suffer from cardiovascular disease globally, only sixteen% of cases are due to genetic traits. This underlines how much room there is to improve on screening and prevention, which is where this device could have such an impact,” said Leopoldt de Bruin, CEO of ESN Cleer. “We’re really pleased to be able to bring these strands together in addressing such a major global health challenge.”

“Often, blood tests are only conducted after a heart failure episode. Such reactive testing is too late, leaving people with debilitating illness or leading to deaths,” said co-director of the RMIT Functional Materials and Microsystems Research Group, Professor Sharath Sriram, PhD. “The ESN Cleer device is able to measure biomarker concentrations a thousand times more accurately than levels founds in human bodily fluids. Prevention is always better than cure, which is where this technology comes in, adding accurate prediction to the mix.”

Related Links:
ESN Cleer
Innovative Manufacturing Cooperative Research Centre
RMIT University

Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Gold Member
Disposable Protective Suit For Medical Use
Disposable Protective Suit For Medical Use
Silver Member
Compact 14-Day Uninterrupted Holter ECG
NR-314P
New
Bilirubin Lamp
Bilibluelight

Print article

Channels

Surgical Techniques

view channel
Image: NTT and Olympus have begun the world\'s first joint demonstration experiment of a cloud endoscopy system (Photo courtesy of Olympus)

Cloud Endoscopy System Enables Real-Time Image Processing on the Cloud

Endoscopes, which are flexible tubes inserted into the body's natural openings for internal examination and biopsy collection, are becoming increasingly vital in medical diagnostics. Their minimal invasiveness... Read more

Patient Care

view channel
Image: The newly-launched solution can transform operating room scheduling and boost utilization rates (Photo courtesy of Fujitsu)

Surgical Capacity Optimization Solution Helps Hospitals Boost OR Utilization

An innovative solution has the capability to transform surgical capacity utilization by targeting the root cause of surgical block time inefficiencies. Fujitsu Limited’s (Tokyo, Japan) Surgical Capacity... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: The PATHFAST hs-cTnI-II high-sensitivity troponin assay has been developed for the PATHFAST Biomarker Analyzer (Photo courtesy of Polymedco)

POC Myocardial Infarction Test Delivers Results in 17 Minutes

Chest pain is the second leading cause of emergency department (ED) visits by adults in the United States, generating over 7 million visits annually. In the event of a suspected heart attack, physicians... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.